• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

TapImmune - Articles and news items

TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study

Industry news / 22 April 2016 / Victoria White, Digital Content Producer

TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer…

FDA grants Fast Track Designation to TapImmune’s TPIV 200

Industry news / 3 February 2016 / Victoria White

The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer…